Related Experiment Video
Updated: Oct 8, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
[Myelotoxicity due to cancer chemotherapy with special reference to autologous bone marrow transplantation]
Abstract:
In order to know the myelotoxicity due to combination cancer chemotherapy, the hematologic changes in 15 patients with non-Hodgkin's lymphoma (NHL) treated with combination chemotherapy using adriamycin, cyclophosphamide, vincristine and prednisolone (ACOP protocol) were observed. From this study, it was confirmed that neutrophil leukocyte depletion is one of the most important dose-limiting factors of combination cancer chemotherapy. Our experience of autologous bone marrow transplantation for 15 patients with malignant tumors, such as NHL, small cell lung cancer, nasopharyngeal carcinoma, clearly demonstrated that cryopreserved autologous bone marrow cells can rescue cancer patients from marrow-lethal doses of drugs and irradiation and thus prompts us to establish a new protocol to eradicate tumor cells.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

